Mapping the Preclinical Phase: The Conserved Sequence of Lung Function Decline in Idiopathic Pulmonary Fibrosis

MedXY Editorial Team•Mar 13, 2026•Clinical Updates

Idiopathic pulmonary fibrosis (IPF) follows a predictable, conserved sequence of lung function decline that begins approximately a decade before clinical diagnosis.
The diffusion capacity for carbon monoxide (DLCO) serves as a sentinel marker, declining steadily starting around 10 years before the disease reaches a threshold of 70%-predicted.
Forced vital capacity (FVC) decline occurs much later and accelerates significantly as the disease progresses, with a 12-fold increase in the rate of decline between the early and late phases.
Estimated years since onset (EYO) is a potent predictor of clinical outcomes, with every one-year increase in EYO associated with a 31% higher risk of death or lung transplant.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Idiopathic pulmonary fibrosis (IPF) follows a predictable, conserved sequence of lung function decline that begins approximately a decade before clinical diagnosis.
The diffusion capacity for carbon monoxide (DLCO) serves as a sentinel marker, declining steadily starting around 10 years before the disease reaches a threshold of 70%-predicted.
Forced vital capacity (FVC) decline occurs much later and accelerates significantly as the disease progresses, with a 12-fold increase in the rate of decline between the early and late phases.
Estimated years since onset (EYO) is a potent predictor of clinical outcomes, with every one-year increase in EYO associated with a 31% higher risk of death or lung transplant.